Matthias Holdhoff
Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center · Stanford Health Care
Credentials: · · · · ·
History
- Present
Brain Cancer disease Group · Stanford Health Care
- Present
- 2006–2008
Medical Oncology
- 2003–2006
Internal Medicine
- 1999–2003
Doctor of Medicine
Research
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017 · 5,443 citations
Detection of circulating tumor DNA in early- and late-stage human malignancies
Science Translational Medicine · 2014 · 3,962 citations
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
New England Journal of Medicine · 2023 · 643 citations
- CB
39 papers · 5 as a resident
- SG
33 papers
- KS
27 papers
- DK
21 papers
17 papers
- PW
17 papers
15 papers · 4 as a resident
- DM
13 papers
Grants
- 2022–2025
National Center for Advancing Translational Sciences · R21
PI · $450.3K · Johns Hopkins University
Clinical trials
- 2026–2029
Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
Principal investigator · Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 2023–2027
Principal investigator · Recruiting · Phase 1, Phase 2
SignPath Pharma, Inc.
- 2012–2017
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Principal investigator · Completed · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 2017–2022
Study chair · Terminated · Phase 1
Basilea Pharmaceutica